Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Obesity is a growing concern in India, contributing to conditions such as type-2 diabetes and cardiovascular ... BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Furthermore, the company's strong research and development pipeline suggests potential for breakthroughs in other therapeutic areas. As Eli Lilly leverages its expertise in diabetes and obesity to ...

There is some expectation that Eli Lilly's pipeline will break through, and analysts are particularly optimistic about diabetes and oncology treatments. Factors including these recent strong ...

Furthermore, the company's strong research and development pipeline suggests potential for breakthroughs in other therapeutic areas. As Eli Lilly leverages its expertise in diabetes and obesity to ...

On Wednesday, Truist Securities reaffirmed their Buy rating on Eli Lilly (NYSE:LLY ... developments in the obesity and cardiometabolic pipeline, with upcoming data expected from various Phase ...

On Wednesday, Truist Securities reaffirmed their Buy rating on Eli Lilly ... pipeline, with upcoming data expected from various Phase 2 trials in 2025. These include Bima for obesity, retatrutide for ...